Malidi Ahamadi

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 158 citations · Full text

Medicine, Pembrolizumab Dosing, Immune Checkpoint Inhibitor +6

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 147 citations · Full text

Pembrolizumab Clearance, Immunology, Metronomic Chemotherapy +18

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 135 citations

Medicine, Pharmacology, Time Dependent Pharmacokinetics +8

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma

MS Chatterjee, Jeroen Elassaiss‐Schaap, Andreas Lindauer et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 79 citations · Full text

Immunology, Pathology, Immunotherapy +18

Prediction of Concentration–Time Profile and its Inter-Individual Variability following the Dermal Drug Absorption

Sebastian Polak, Cyrus Ghobadi, Himanshu Mishra et al. · Journal of Pharmaceutical Sciences · 2012 · 66 citations

Medicine, Dermal Drug Absorption, Inter-individual Variability +8